At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 42 enrolled
Drug / intervention
ABP 959 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Active-Controlled Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
In Brief
A Phase 3 clinical trial evaluating ABP 959 and Eculizumab for Paroxysmal Nocturnal Hemoglobinuria. Completed, enrolled 42 participants across 24 sites in 14 countries.
Detailed Summary
This is a randomized, double-blind, active-controlled phase 3 study of ABP 959 in participants with paroxysmal nocturnal hemoglobinuria.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParoxysmal Nocturnal Hemoglobinuria
CountriesCzechia, Finland, France, Ireland, Italy, Netherlands, Norway, Portugal, Slovenia, Spain, Sweden, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
First PostedJan 2019
Primary CompletionJul 2022
TodayJul 2026
First PostedJan 28, 2019
Enrollment StartJan 22, 2019
Primary CompletionJul 12, 2022
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 7.4 years ago
Interventions
ABP 959drug
intravenous infusion
Eculizumabdrug
intravenous infusion